<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386282</url>
  </required_header>
  <id_info>
    <org_study_id>1.1.4</org_study_id>
    <nct_id>NCT00386282</nct_id>
  </id_info>
  <brief_title>Acceptability and Feasibility of Medical Abortion Using Mifepristone and Buccal Misoprostol</brief_title>
  <official_title>Acceptability and Feasibility of Medical Abortion in Mexico, Puerto Rico, Armenia and Azerbaijan: A Study of Buccal Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days' Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examined the acceptability and feasibility of introducing a
      mifepristone-misoprostol regimen of medical abortion into abortion services in two private
      clinics in Puerto Rico; 2 clinics in Baku, Azerbaijan; 3 clinics in Yerevan, Armenia; and 4
      clinics in Mexico City. It was hypothesized that the study regimen would be both acceptable
      and efficacious.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study recruited women with pregnancies up to 63 days gestation. Eligible women took 200
      mg mifepristone, followed by 800 buccal misoprostol. They later underwent clinic follow-up to
      determine if their medical abortions were complete. The study assessed the acceptability and
      feasibility of the above regimen and sought to determine the efficacy and acceptability of
      buccal administration of misoprostol as well as the acceptability of side effects experienced
      by women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>acceptability</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1250</enrollment>
  <condition>Abortion, First Trimester</condition>
  <arm_group>
    <arm_group_label>mifepristone-misoprostol treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mifepristone-misoprostol treatment</intervention_name>
    <description>200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.</description>
    <arm_group_label>mifepristone-misoprostol treatment</arm_group_label>
    <other_name>medical abortion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestation up to 63 days

          -  General good health

          -  Willingness to provide contact information for follow-up

          -  Absence of conditions which contraindicate the use of mifepristone and misoprostol for
             pregnancy termination

        Exclusion Criteria:

          -  Ectopic pregnancy

          -  Intrauterine device (IUD) in place
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hector Diaz Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica de Planificacion Familiar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Arredondo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Metropolitan Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gulnara Rzaeva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Research Institute of Obstetrics &amp; Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Besti Muradova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Family Planning Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanna Fildjyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Perinatology, Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armine Harutyunyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Family Planning and Sexual Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Aghajanyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ranulfo Rios, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H G Enrique Cabrera</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Garcia Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H.M.I Inguaran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio E Flores, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>C S Beatriz Velasco Aleman</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elba Margarita Lugo Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>C S Santa Catarina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Family Planning and Sexual Health</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Perinatology, Obstetrics and Gynecology</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical University</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Planning Center</name>
      <address>
        <city>Baku</city>
        <country>Azerbaijan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Obstetrics and Gynecology</name>
      <address>
        <city>Baku</city>
        <country>Azerbaijan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Beatriz Velasco Aleman</name>
      <address>
        <city>Mexico City</city>
        <state>Federal District</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Santa Catarina</name>
      <address>
        <city>Mexico City</city>
        <state>Federal District</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.G. Enrique Cabrera</name>
      <address>
        <city>Mexico City</city>
        <state>Federal District</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.M.I Inguaran</name>
      <address>
        <city>Mexico City</city>
        <state>Federal District</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Planificacion Familiar</name>
      <address>
        <city>Lomas Verdes, Bayamon</city>
        <zip>00956</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woman's Metropolitan Center</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Armenia</country>
    <country>Azerbaijan</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2006</study_first_submitted>
  <study_first_submitted_qc>October 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mifepristone</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Buccal administration</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

